Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of leading experts discuss the pathophysiology of cold agglutinin disease (CAD), the steps needed for an accurate diagnosis, and how emerging treatment options are changing the management of patients with primary CAD.  The experts Prof. Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA,  Prof. Bernd Jilma, Medical University of Vienna, Austria,  Dr Shirley D'Sa, University College London Hospitals, UK This touchPODCAST is for HCPs only.  This activity is funded by an independent medical education grant from Sanofi and is jointly provided by USF Health and touchIME.  For further information visit: https://touchoncologyime.org/understanding-the-immunopathogenesis-of-cad-what-are-the-implications-of-new-and-emerging-therapies